Survival outcomes following treatment delays among patients with early-stage female cancers: a nationwide study

Table 3 Univariate and Multivariable analyses of the association of treatment delay intervals with overall survival

Cancer	Subgroup^d	Model 1		Model 2^a
Cancer	Subgroup^d	HR^b (95% CI)	P	HR (95% CI)	P
NSCLC
Stage I	Intermediate	1.47 (1.36–1.58)	< 0.001	1.04 (0.95–1.13)	0.349
Stage I	Long	2.05 (1.85–2.25)	< 0.001	1.11 (1.01–1.23)	0.044
Stage II	Intermediate	1.20 (1.07–1.33)	0.001	0.97 (0.87–1.09)	0.699
Stage II	Long	1.48 (1.28–1.70)	< 0.001	1.00 (0.86–1.16)	0.995
IBC
Stage I	Intermediate	0.91 (0.86–0.96)	0.001	0.92 (0.87–0.97)	0.003
Stage I	Long	1.20 (1.08–1.34)	< 0.001	1.23 (1.11–1.37)	< 0.001
Stage II	Intermediate	0.86 (0.82–0.90)	< 0.001	0.93 (0.88–0.97)	0.002
Stage II	Long	1.10 (1.01–1.20)	0.038	1.09 (0.99–1.19)	0.059
DTC
Stage I	Intermediate	0.43 (0.33–0.57)	< 0.001	0.70 (0.53–0.93)	0.012
Stage I	Long	0.76 (0.49–1.19)	0.236	1.09 (0.70–1.70)	0.711
Stage II	Intermediate	0.74 (0.43–1.29)	0.295	0.73 (0.41–1.31)	0.300
Stage II	Long	0.21 (0.03–1.50)	0.120	0.22 (0.03–1.61)	0.138
Colorectal cancer
Stage I	Intermediate	0.97 (0.88–1.06)	0.503	0.83 (0.75–0.92)	< 0.001
Stage I	Long	1.60 (1.29–2.00)	< 0.001	1.21 (0.97–1.52)	0.090
Stage II	Intermediate	0.71 (0.66–0.76)	< 0.001	0.70 (0.65–0.75)	< 0.001
Stage II	Long	1.32 (1.11–1.57)	0.001	0.87 (0.72–1.04)	0.120
Cervical cancer
Stage I	Intermediate	1.75 (1.48–2.08)	< 0.001	1.08 (0.90–1.30)	0.421
Stage I	Long	1.70 (1.28–2.26)	< 0.001	0.84 (0.63–1.14)	0.282
Stage II	Intermediate	1.04 (0.85–1.27)	0.713	0.92 (0.74–1.14)	0.436
Stage II	Long	1.15 (0.86–1.54)	0.340	1.01 (0.75–1.37)	0.949

HR hazard ratio, CI confidence interval, NSCLC non-small cell lung cancer, IBC infiltrating breast cancer, DTC differentiated thyroid carcinoma
^aModel 2 was adjusted by the age, race, tumor location (exception of DTC, cervical cancer), differentiated grade; histology (exception of colorectal cancer), T stage, N stage (exception of NSCLC in stage I, DTC in stage II, colorectal cancer), surgery (exception of DTC), radiotherapy, chemotherapy (exception of DTC), marital status, income, and molecular subtype (only for breast cancer)
^bHR: compared with immediate treatment initiation
^cCervical cancer: FIGO stage
^dSubgroup: immediate: < 1 month, intermediate delayed: ≥ 1 and ≤ 2 months, and long-delayed: ≥ 3 months
Bold values indicate statistical significance (p < 0.05)

ISSN: 1479-5876